Development of next-generation mass spectrometry-based DE novo RNA sequencing for all modifications

Active Project Grant Awarded Last action

Award ID
R01HG012853
Recipient
Awarding agency
Obligated
$8,205,767

Award facts

Assistance listing
93.172 Human Genome Research
Completion date 93% complete
Originally
Place of performance
Albany, NY 12222, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
An RNA sequence with all its diverse modifications constitutes 'true' information content of the RNA. Defects in RNA modifications account for >100 human diseases, such as breast cancer, type-2 diabetes and obesity, affecting millions of americans. Despite its significance, the true sequence of a RNA, i.e., identity and location of each and every nucleotide building block (modified or not) within a full-length RNA, remains a mystery, mainly because of the lack of a general method to directly sequence any nucleotide, especially modified nucleotides (including unknown ones) at single-nucleotide resolution. No existing technology can sequence all modifications simultaneously to unfold the true RNA sequences at a large scale or the transcriptomic level. What complicates RNA modification studies is that >170 modification types have been discovered, and not all of nucleotide modifications are modified completely to 100% at their RNA sites. They are even undetectable by NGS-based technologies, which require the conversion of RNA to cdnas that do not have any modification information. Tools to map RNA modifications are limited only to a few popular modifications, and can usually analyze only one modification type at a time. Mass spectrometry (MS) is currently the only technique that can characterize all RNA modifications; however, conventional MS methods lose information regarding the location and CO-occurrence of modified nucleotides. To resolve these outstanding issues, we have recently developed a series of novel next generation mass spectrometry-based sequencing (nextgen massspec-SEQ) approaches that can DE novo directly sequence trnas without a cdna and can sequence and quantify all nucleotide modifications simultaneously. For the duration of this proposal, we will further develop nextgen massspec-SEQ to sequence trnas efficiently in different cellular and even disease conditions, make IT scalable toward high throughput, and expand its application to simultaneously sequence and map all modifications quantitatively on any RNA type and at the transcriptomic level. Specifically, we propose to develop MS for large-scale DE novo sequencing of full-length trnas, together with all diverse nucleotide modifications (aim 1), empower MS to simultaneously sequence and quantify multiple RNA modifications, allowing quantitative mapping at single nucleotide and stoichiometric precision (aim 2), scale up nextgen massspec-SEQ and combine IT with high-throughput NGS sequencing for direct sequencing of diverse RNA modifications at the transcriptomic level (aim 3). Our tool will address a long- standing issue of how to reveal the 'true" RNA sequences and provide a transformative tool for studying RNA modifications, which will promote better understanding of functions of post-transcriptional modifications and their correlations to RNA-related diseases and pandemics.

Transactions

Action Obligated Date
Amendment $617,230
Amendment $66,038
Amendment $66,038
Amendment $66,038
Amendment $594,340
Amendment $594,340
Amendment $594,340
Amendment $594,340
Amendment $0
Amendment $212,097
Amendment $212,097
Amendment -$212,097
Amendment $0
Amendment $354,295
Amendment $354,295
Amendment $354,295
Amendment $354,295
Amendment -$338,000
Amendment -$338,000
Amendment -$338,000
Amendment $52,038
Amendment $52,038
Amendment $52,038
Amendment $52,038
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $585,448
Amendment $585,448
Amendment $585,448
Amendment $585,448
Amendment $585,448
Amendment $585,448
Amendment $0
Original award $676,946
Show all 37

Subawards

Subrecipient Amount Awarded
Robert S Fujinami PHD The Chen Lab has been actively involved in investigating the functional roles of tRNA derived small RNAs (tsRNAs) and their RNA modifications in various… $166,030
The Trustees Of Columbia University In The City Of New York The goal of the overall project is to use a de novo mass spectrometry ladder complementation sequencing method (NextGen MassSpec-Seq, NG-MS-Seq) developed by… $94,056

Quick answers

Who received award R01HG012853?

R01HG012853 was awarded to The Research Foundation For The State University Of New York by National Human Genome Research Institute (National Institutes of Health) on February 23, 2023.

How much is award R01HG012853 worth?

$8,205,767 has been obligated on R01HG012853.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login